Successful remission induction therapy with gilteritinib in a patient with de novo FLT3‐mutated acute myeloid leukaemia and severe COVID‐19

The optimal treatment for patients with newly diagnosed acute myeloid leukaemia (AML) who are infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/COVID-19 is unknown.1 We report the case of a previously fit 27-year-old male who presented with a 3-day history of fever (\u003e39 C), swollen, erythematous elbows and no respiratory symptoms. His white blood count (WBC) was 187×109 /L and bone marrow (Figure 1A \u0026 1C) examination revealed normal karyotype AML with a fms related receptor tyrosine kinase 3 (FLT3) internal tandem duplication (ITD), wild-type NPM1 and no additional mutations on a next-generation sequencing panel.